Neoadjuvant chemoradiotherapy plus PD-1 blockade for high or very high-risk locally advanced rectal cancer

被引：0
|
作者：
Liu, X. [1 ]
He, L. [2 ]
Tong, W. [2 ]
Li, S. [2 ]
Wang, Z. [1 ]
Gu, M. [1 ]
Li, Y. [1 ]
Liu, Z. [1 ]
Chang, P. [1 ]
Wang, Q. [2 ]
机构：
[1] First Hosp Jilin Univ, Dept Radiat Oncol & Therapy, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Dept Gastrocolorectal Surg, Gen Surg Ctr, Changchun, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.annonc.2024.05.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
252P
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [21] Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer
    Nierengarten, Mary Beth
    CANCER, 2025, 131 (02)
  • [22] BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer
    Rob, Glynne-Jones
    Marcia, Hall
    Sarah, Pearce
    Sam, Bosompem
    John, Bridgewater
    Ian, Chau
    Harpreet, Wasan
    Brendan, Moran
    Sandra, Beare
    Andre, Lopes
    Nick, West
    Phil, Quirke
    Wai-Lup, Wong
    Mark, Harrison
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Neoadjuvant Chemotherapy Rather than Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer with High Tumor Burden
    Koca, Dogan
    Oztop, Ilhan
    Yilmaz, Ugur
    HEPATO-GASTROENTEROLOGY, 2012, 59 (119) : 2151 - 2154
  • [24] Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
    Xiao, Weiwei
    Luo, Huilong
    Yao, Ye
    Wang, Yaqin
    Liu, Shuang
    Sun, Rui
    Chen, Gong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study
    Yang, Zhengyang
    Gao, Jiale
    Zheng, Jianyong
    Han, Jiagang
    Li, Ang
    Liu, Gang
    Sun, Yi
    Zhang, Jie
    Chen, Guangyong
    Xu, Rui
    Zhang, Xiao
    Liu, Yishan
    Bai, Zhigang
    Deng, Wei
    He, Wei
    Yao, Hongwei
    Zhang, Zhongtao
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [26] Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study
    Zhengyang Yang
    Jiale Gao
    Jianyong Zheng
    Jiagang Han
    Ang Li
    Gang Liu
    Yi Sun
    Jie Zhang
    Guangyong Chen
    Rui Xu
    Xiao Zhang
    Yishan Liu
    Zhigang Bai
    Wei Deng
    Wei He
    Hongwei Yao
    Zhongtao Zhang
    Signal Transduction and Targeted Therapy, 9
  • [27] Neoadjuvant S-1 and oxaliplatin plus bevacizumab therapy for high-risk locally advanced rectal cancer: A prospective multicenter phase II study
    Miura, Takuya
    Morohashi, Hajime
    Sakamoto, Yoshiyuki
    Kagiya, Takuji
    Hasebe, Tatsuya
    Nakayama, Yoshihito
    Fujita, Hiromasa
    Hakamada, Kenichi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (01): : 71 - 79
  • [28] The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
    Michael, M.
    Wong, R.
    Gill, S.
    Strickland, A.
    Pavlakis, N.
    Shapiro, J.
    Link, E.
    Farrell, M.
    Ngan, S.
    Heriot, A.
    Goldstein, D.
    Mitchell, C.
    Wilson, K.
    Mui, M.
    Ramsay, R.
    Segelov, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S450 - S450
  • [29] Neoadjuvant chemoradiotherapy and chemotherapy in patients with locally advanced rectal cancer
    Soliman, A.
    Attia, N.
    Khalaf, M.
    Attia, A.
    Fakhry, H.
    ANNALS OF ONCOLOGY, 2016, 27 : 93 - 93
  • [30] Neoadjuvant chemoradiotherapy for locally advanced rectal cancer:The debate continues
    Francesca De Felice
    Daniela Musio
    Luciano Izzo
    Vincenzo Tombolini
    World Journal of Gastrointestinal Oncology, 2014, (12) : 438 - 440
12345